Oral naloxone antagonizes loperamide-induced delay of orocecal transit.
Orocecal transit time was determined by the lactulose hydrogen breath test in nine healthy volunteers after administration of placebo, loperamide (16 mg per os), and loperamide (16 mg per os) followed by oral naloxone at doses of 16 and 32 mg. The four tests were performed in double-blind conditions and in random sequences. Transit time (mean, SD) after loperamide (128.8 min, 32.9) was significantly increased (P less than 0.05) compared with placebo (85.5 min, 35.7), loperamide followed by naloxone 16 mg (88.8 min, 46.2), and loperamide followed by naloxone 32 mg (84.4 min, 40.6). These results show that the peripheral opioid agonist loperamide delays orocecal transit in healthy subjects and that naloxone per os at adequate doses antagonizes this effect.
D000284:Administration, Oral; D000328:Adult; D001944:Breath Tests; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D005769:Gastrointestinal Motility / Q000187:drug effects*; D006801:Humans; D006859:Hydrogen / Q000032:analysis; D007792:Lactulose; D008139:Loperamide / Q000037:antagonists & inhibitors*; D008297:Male; D009055:Mouth / Q000502:physiology; D009270:Naloxone / Q000008:administration & dosage / Q000494:pharmacology*; D010880:Piperidines / Q000037:antagonists & inhibitors*; D011897:Random Allocation
D010880:Piperidines; D009270:Naloxone; D007792:Lactulose; D008139:Loperamide; D006859:Hydrogen